Descripción del proyecto
Vendajes patentados para el tratamiento de las heridas crónicas
El tratamiento de las heridas crónicas no cicatrizantes representa una necesidad médica no cubierta por los apósitos convencionales, que no logran proteger contra las infecciones recurrentes y esto da lugar a un aumento de la mortalidad. Esta situación se ve exacerbada por la creciente incidencia de la diabetes y la obesidad, así como de la resistencia a los antibióticos. El proyecto financiado con fondos europeos WHILYAS-2 propone abordar el tratamiento insuficiente de las heridas crónicas a través de una tecnología patentada que utilice las quimiocinas como agentes terapéuticos a través de la administración local a partir de bacterias del ácido láctico modificadas genéticamente. Para la prueba de concepto a nivel clínico, los socios llevarán a cabo un ensayo clínico de fase II de su posible fármaco ILP100 tópico en enfermos de diabetes.
Objetivo
ILYA PHARMA AB is a Swedish spin-out biotech company from Uppsala that develops next-generation biologics to treat wounds in skin and mucosa.
In the previous SME Instrument project, the Company reached the First in Human (FiH) Phase I clinical trial in the development of their technology platform (ILP) that utilizes chemokines as therapeutic agents through local administration from genetically modified lactic acid bacteria.
The WHILYAS-2 project addresses several critical problems and unmet medical needs related to the treatment of chronic wounds, both from patients and healthcare perspectives, namely the pandemic of obesity and diabetes (463 million people in 2019), an alarming pace of antibiotic resistance spreading (due to overuse of antibiotics), limited and insufficient treatment options (less than 25% of chronic wounds heal within 12 weeks), and vast and growing socio-economic burden (20 billion EUR per year in the US and Europe alone).
The technical, industrial, legal, and commercial feasibility of ILP100 Topical have all been confirmed over the course of our previous activities and developments.
In this project, Ilya Pharma intends to conduct exploratory clinical trials (Phase IIa) of their drug candidate, ILP100 Topical, in treatment of non-healing (chronic) wounds in populations with diabetes to achieve clinical Proof of Concept (PoC) in the relevant patient group. WHILYAS-2 will allow the Company to scale up and position it to be further investable for VCs and MedTech/Biopharma Companies or license ILP100 Topical to a partner capable of bringing it to the market through large-scale Phase IIb or pivotal (Phase III) clinical studies.
If these efforts are successful, ILP100 Topical is expected to be superior and best in class treatment for chronic wounds, offering ease of use, comparable to traditional wound dressings, >50% reduction of wound infections, significantly reduced 5-year mortality, as well as >50% decrease in treatment cost per wound.
Ámbito científico
Not validated
Not validated
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health scienceshealth sciencespublic healthepidemiologypandemics
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-EIC-SMEInst-2018-2020-3
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
752 37 Uppsala
Suecia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.